MCID: MLG077
MIFTS: 60

Malignant Peripheral Nerve Sheath Tumor

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Malignant Peripheral Nerve Sheath Tumor

MalaCards integrated aliases for Malignant Peripheral Nerve Sheath Tumor:

Name: Malignant Peripheral Nerve Sheath Tumor 12 53 59 15 73
Malignant Neurilemmoma 53 59 55
Neurofibrosarcoma 53 59 73
Mpnst 53 59 55
Malignant Neurofibroma 53 59
Malignant Schwannoma 53 59
Neurogenic Sarcoma 53 59
Malignant Neoplasm of the Peripheral Nerve Sheath 12
Malignant Peripheral Nerve Sheath Tumors 55

Characteristics:

Orphanet epidemiological data:

59
malignant peripheral nerve sheath tumor
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide); Age of onset: Adolescent,Adult,Childhood,Elderly,Infancy; Age of death: adolescent,adult,early childhood,elderly,infantile,late childhood,young Adult;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:5940
MeSH 44 D009442
NCIt 50 C3798
Orphanet 59 ORPHA3148
UMLS via Orphanet 74 C0751690 C0206729
ICD10 via Orphanet 34 C47.9
UMLS 73 C0751690

Summaries for Malignant Peripheral Nerve Sheath Tumor

NIH Rare Diseases : 53 A malignant peripheral nerve sheath tumor (MPNST) is a tumor that develops in the protective lining that covers nerves. The first symptom of MPNST is often a lump or mass that increases in size, sometimes causing pain or a tingling sensation. MPNST is considered an aggressive tumor because there is up to a 65% chance of the tumor regrowing after surgery (a recurrence), and approximately 40% chance of spreading to distant parts of the body (a metastasis), most commonly to the lung. Treatment of MPNST begins with surgery to remove as much of the tumor as possible. Radiation therapy may be used to decrease the chance of a recurrence. Chemotherapy might be used if the whole tumor cannot be removed during surgery, or to treat a metastasis. MPNSTs are quite rare, occurring in 0.001% of the general population.  Approximately 25-50% of MPNSTs are associated with a genetic condition known as neurofibromatosis type 1.

MalaCards based summary : Malignant Peripheral Nerve Sheath Tumor, also known as malignant neurilemmoma, is related to malignant triton tumor and epithelioid malignant peripheral nerve sheath tumor. An important gene associated with Malignant Peripheral Nerve Sheath Tumor is HTRA1 (HtrA Serine Peptidase 1), and among its related pathways/superpathways are ERK Signaling and Cytokine Signaling in Immune system. The drugs Doxorubicin and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and kidney, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 A malignant peripheral nerve sheath tumor (MPNST) (also known as \"malignant schwannoma\",... more...

Related Diseases for Malignant Peripheral Nerve Sheath Tumor

Diseases related to Malignant Peripheral Nerve Sheath Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 308)
# Related Disease Score Top Affiliating Genes
1 malignant triton tumor 34.4 NF1 S100B
2 epithelioid malignant peripheral nerve sheath tumor 34.0 MUC1 NF1 S100B SMARCB1
3 neurofibromatosis, type i 32.3 KIT NF1 PDGFRA
4 neurofibromatosis, type iv, of riccardi 31.9 KIT NF1 NF2 PDGFRA
5 neurofibroma 31.0 CDKN2A KIT MUC1 NF1 NF2 PDGFRA
6 malignant spindle cell melanoma 31.0 KIT NF1 SOX10
7 soft tissue sarcoma 30.9 EGFR MDM2 TP53
8 angiosarcoma 30.8 KIT MUC1 VIM
9 perineurioma 30.6 KIT MUC1 S100B VIM
10 peritoneal mesothelioma 30.6 CDKN2A EGFR MUC1 NF2
11 monophasic synovial sarcoma 30.5 MUC1 S100B VIM
12 neuroma 30.2 NF1 NF2 S100B SMARCB1
13 sarcoma, synovial 30.2 KIT MDM2 MUC1 VIM
14 adenocarcinoma 29.7 CDK4 CDKN2A EGFR KIT MUC1 TP53
15 liposarcoma 29.7 CDK4 CDKN2A MDM2 TP53 VIM
16 hemangiopericytoma, malignant 29.0 ACTC1 MDM2 MUC1 S100B VIM
17 glioma 28.9 CDK4 CDKN2A EGFR MDM2 NF1 PDGFRA
18 dedifferentiated liposarcoma 28.8 ACTC1 CDK4 CDKN2A MDM2 MUC1 TP53
19 rhabdomyosarcoma 28.5 ACTC1 CDK4 MDM2 PDGFRA TP53 VIM
20 cellular schwannoma 28.5 CDKN2A MDM2 NF1 NF2 S100A1 S100B
21 neurilemmoma 28.2 KIT NF1 NF2 PDGFRA S100B SMARCB1
22 gastrointestinal stromal tumor 27.6 ACTC1 CDKN2A EGFR KIT NF1 PDGFRA
23 ewing sarcoma 27.4 CDKN2A EGFR KIT MDM2 PDGFRA S100A1
24 malignant peripheral nerve sheath tumor with perineurial differentiation 12.5
25 neurofibrosarcoma 12.2
26 childhood malignant schwannoma 12.0
27 adult malignant schwannoma 12.0
28 malignant glandular tumor of peripheral nerve sheath 11.6
29 melanocytic psammomatous mpnst 11.3
30 malignant melanocytic neoplasm of the peripheral nerve sheath 11.3
31 chromosome 17q11.2 deletion syndrome, 1.4-mb 11.2
32 chromosome 17q11.2 deletion syndrome 11.2
33 gliofibroma 11.0 NF1 TP53
34 brain stem astrocytic neoplasm 11.0 CDKN2A TP53
35 brain ependymoma 11.0 EGFR TP53
36 localized hypertrophic neuropathy 10.9 MUC1 S100B
37 sclerosing perineurioma 10.9 MUC1 S100B
38 oropharynx cancer 10.9 CDKN2A EGFR TP53
39 cerebral convexity meningioma 10.9 NF2 TP53
40 basaloid squamous cell carcinoma 10.8 CDKN2A EGFR TP53
41 juvenile pilocytic astrocytoma 10.8 CDKN2A NF1 TP53
42 neurofibromatosis, familial spinal 10.8 NF1 NF2
43 cervical adenosquamous carcinoma 10.8 CDKN2A EGFR PDGFRA
44 vulva cancer 10.8 CDKN2A EGFR TP53
45 pre-malignant neoplasm 10.8 CDKN2A EGFR TP53
46 microglandular adenosis 10.8 EGFR S100B TP53
47 penile cancer 10.8 CDKN2A EGFR TP53
48 plexiform schwannoma 10.8 KIT NF1 NF2
49 in situ carcinoma 10.8 CDKN2A EGFR TP53
50 pharynx cancer 10.8 CDKN2A EGFR TP53

Graphical network of the top 20 diseases related to Malignant Peripheral Nerve Sheath Tumor:



Diseases related to Malignant Peripheral Nerve Sheath Tumor

Symptoms & Phenotypes for Malignant Peripheral Nerve Sheath Tumor

GenomeRNAi Phenotypes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

26 (show all 47)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.25 EGFR
2 Decreased viability GR00173-A 10.25 PDGFRA
3 Decreased viability GR00221-A-1 10.25 EGFR KIT CDKN2A NF1 PDGFRA SMARCB1
4 Decreased viability GR00221-A-2 10.25 NF1 SMARCB1
5 Decreased viability GR00221-A-3 10.25 CDKN2A PDGFRA SMARCB1
6 Decreased viability GR00221-A-4 10.25 EGFR CDKN2A NF1 PDGFRA
7 Decreased viability GR00301-A 10.25 KIT
8 Decreased viability GR00381-A-1 10.25 SMARCB1
9 Decreased viability GR00402-S-2 10.25 EGFR KIT CDKN2A NF1 PDGFRA SMARCB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.03 S100B SMARCB1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.03 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.03 SOX10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.03 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.03 SMARCB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.03 CDK4 SOX10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.03 CDK4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.03 EGFR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.03 EGFR
19 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.03 SMARCB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.03 VIM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.03 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.03 KIT
23 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.03 KIT
24 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.03 VIM SMARCB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.03 VIM SOX10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.03 VIM
27 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.03 EGFR VIM
28 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.03 SMARCB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.03 CDK4 EGFR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.03 EGFR
31 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.03 VIM
32 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.03 KIT VIM
33 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.03 SOX10
34 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.03 KIT CDK4
35 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.03 EGFR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.03 CDK4
37 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.03 SOX10
38 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.03 S100B VIM
39 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.03 SOX10
40 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.03 SOX10
41 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.03 SOX10
42 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.03 SMARCB1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.03 S100B SMARCB1 KIT CDK4 EGFR SOX10
44 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.03 KIT
45 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.03 KIT
46 Decreased cell migration GR00055-A-1 9.73 CDK4 MUC1 NF1 NF2 EGFR VIM
47 Increased proliferation GR00094-A 9.13 SMARCB1 NF2 TP53

MGI Mouse Phenotypes related to Malignant Peripheral Nerve Sheath Tumor:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.48 NF1 MDM2 NF2 S100A1 S100B PDGFRA
2 cardiovascular system MP:0005385 10.47 NF1 S100A1 PDGFRA SH3PXD2A SMARCB1 TP53
3 homeostasis/metabolism MP:0005376 10.47 NF1 MDM2 NF2 S100A1 S100B PDGFRA
4 cellular MP:0005384 10.44 NF1 MDM2 PDGFRA S100A1 TP53 SOX10
5 growth/size/body region MP:0005378 10.44 NF2 NF1 MDM2 SH3PXD2A PDGFRA TP53
6 embryo MP:0005380 10.42 NF1 NF2 PDGFRA SH3PXD2A SOX10 SMARCB1
7 mortality/aging MP:0010768 10.36 NF1 MDM2 PDGFRA SH3PXD2A NF2 SOX10
8 digestive/alimentary MP:0005381 10.35 NF1 MDM2 PDGFRA SH3PXD2A SOX10 SMARCB1
9 endocrine/exocrine gland MP:0005379 10.34 NF2 NF1 MDM2 SH3PXD2A PDGFRA TP53
10 immune system MP:0005387 10.34 NF1 MDM2 PDGFRA NF2 SH3PXD2A SMARCB1
11 hematopoietic system MP:0005397 10.32 NF1 MDM2 PDGFRA SH3PXD2A SMARCB1 TP53
12 muscle MP:0005369 10.31 NF1 S100A1 PDGFRA SH3PXD2A SMARCB1 TP53
13 integument MP:0010771 10.29 NF2 NF1 MDM2 S100B PDGFRA SOX10
14 nervous system MP:0003631 10.27 NF2 NF1 MDM2 SH3PXD2A PDGFRA TP53
15 craniofacial MP:0005382 10.22 NF1 MDM2 PDGFRA NF2 SH3PXD2A TP53
16 liver/biliary system MP:0005370 10.22 NF2 NF1 MDM2 SH3PXD2A SMARCB1 TP53
17 neoplasm MP:0002006 10.22 NF2 NF1 PDGFRA SMARCB1 TP53 SOX10
18 normal MP:0002873 10.14 NF1 MDM2 S100A1 S100B PDGFRA SOX10
19 limbs/digits/tail MP:0005371 10.08 NF1 MDM2 PDGFRA SOX10 TP53 EGFR
20 hearing/vestibular/ear MP:0005377 10.06 NF1 NF2 SH3PXD2A TP53 KIT EGFR
21 pigmentation MP:0001186 10.02 NF1 PDGFRA SOX10 TP53 EGFR CDKN2A
22 reproductive system MP:0005389 10 NF2 MDM2 SH3PXD2A PDGFRA TP53 SMARCB1
23 no phenotypic analysis MP:0003012 9.98 MDM2 PDGFRA SOX10 TP53 CDKN2A KIT
24 renal/urinary system MP:0005367 9.97 NF1 MDM2 SH3PXD2A NF2 PDGFRA TP53
25 respiratory system MP:0005388 9.9 NF1 NF2 S100A1 PDGFRA SH3PXD2A SOX10
26 skeleton MP:0005390 9.65 NF1 MDM2 PDGFRA NF2 SH3PXD2A TP53
27 vision/eye MP:0005391 9.36 NF1 NF2 SH3PXD2A SMARCB1 TP53 VIM

Drugs & Therapeutics for Malignant Peripheral Nerve Sheath Tumor

Drugs for Malignant Peripheral Nerve Sheath Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
4
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
5
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
10
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
11
Epirubicin Approved Phase 3 56420-45-2 41867
12
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
13
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
14
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
15
Cyproheptadine Approved Phase 3 129-03-3 2913
16
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
18
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
19 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
22 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
24 Imatinib Mesylate Phase 2, Phase 3,Phase 1 220127-57-1 123596
25 Nucleic Acid Synthesis Inhibitors Phase 3
26 Etoposide phosphate Phase 3,Phase 2
27 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
28 Anti-Infective Agents Phase 3,Phase 2,Phase 1
29 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
30 Antirheumatic Agents Phase 3,Phase 1
31 Antimitotic Agents Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
33 Antimetabolites Phase 3,Phase 2,Phase 1
34 Antiviral Agents Phase 3,Phase 2,Phase 1
35 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
36
Histamine Phosphate Phase 3 51-74-1 65513
37 Serotonin Agents Phase 3
38 Serotonin Antagonists Phase 3
39 Gastrointestinal Agents Phase 3
40 Neurotransmitter Agents Phase 3
41 Histamine Antagonists Phase 3
42 Histamine H1 Antagonists Phase 3
43 Dermatologic Agents Phase 3
44 Anti-Allergic Agents Phase 3
45 Antipruritics Phase 3
46
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
47
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
48
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
49
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
50
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
6 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
7 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
11 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
12 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
13 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
14 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
17 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
18 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
19 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
20 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
21 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
22 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
23 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
24 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
25 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
26 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
27 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
28 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
29 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
30 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
31 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
32 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
33 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
34 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
35 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
36 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
37 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
38 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02986919 Phase 2 CPI-0610
39 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
40 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
41 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
42 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
43 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
44 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
45 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
46 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Active, not recruiting NCT01661283 Phase 2 everolimus;bevacizumab
47 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Active, not recruiting NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
48 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
49 Trial of Dasatinib in Advanced Sarcomas Active, not recruiting NCT00464620 Phase 2 Dasatinib
50 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Malignant Peripheral Nerve Sheath Tumors Not yet recruiting NCT03433183 Phase 2 Selumetinib;Vistusertib

Search NIH Clinical Center for Malignant Peripheral Nerve Sheath Tumor

Genetic Tests for Malignant Peripheral Nerve Sheath Tumor

Anatomical Context for Malignant Peripheral Nerve Sheath Tumor

MalaCards organs/tissues related to Malignant Peripheral Nerve Sheath Tumor:

41
Lung, Bone, Kidney, Testis, Cervix, Prostate, Liver

Publications for Malignant Peripheral Nerve Sheath Tumor

Articles related to Malignant Peripheral Nerve Sheath Tumor:

(show top 50) (show all 609)
# Title Authors Year
1
Malignant peripheral nerve sheath tumor of the trigeminal nerve involving the middle and posterior cranial fossa. ( 29408426 )
2018
2
Malignant peripheral nerve sheath tumor: The need to get it right first time around. ( 29115724 )
2018
3
Malignant peripheral nerve sheath tumor of the scalp: Two rare case reports. ( 29900032 )
2018
4
Case Report: Metastasis of a Trigeminal Malignant Peripheral Nerve Sheath Tumor to the Corpus Callosum. ( 29518229 )
2018
5
Atypical presentation of a primary cardiac malignant peripheral nerve sheath tumor. ( 29318408 )
2018
6
Targeted next-generation sequencing of malignant peripheral nerve sheath tumor of the pterygopalatine fossa with intracranial metastatic recurrence. ( 29369179 )
2018
7
Case of an Intracranial Malignant Peripheral Nerve Sheath Tumor in the Setting of Pacer-dependent Heart Block. ( 29492148 )
2018
8
Immunohistochemical analysis of epigenetic factors to differentiate malignant peripheral nerve sheath tumor from benign neurofibroma in a patient with mosaic neurofibromatosis type 1: H3 lysine 27 trimethylation stain and enhancer of zeste homolog 2 stain. ( 29687471 )
2018
9
Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma: A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status. ( 29309298 )
2018
10
Extensive perineural spread of an intrapelvic sciatic malignant peripheral nerve sheath tumor: a case report. ( 29974241 )
2018
11
Low- Grade Malignant Peripheral Nerve Sheath Tumor Mimicking a Schwannoma: The Role and Importance of Trimethylated H3K27M Staining. ( 29909207 )
2018
12
Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. ( 29220302 )
2018
13
Malignant Peripheral Nerve Sheath Tumor in a Patient With BAP1 Tumor Predisposition Syndrome. ( 29061454 )
2018
14
Retrobulbar malignant peripheral nerve sheath tumor in a golden retriever dog: A challenging diagnosis. ( 29606723 )
2018
15
CASE SERIES: Malignant Peripheral Nerve Sheath Tumor in the Course of the Mandibular Nerve. ( 29883816 )
2018
16
Supraclavicular Brachial Plexus Neurolysis for a Malignant Peripheral Nerve Sheath Tumor: A Case Report. ( 29894352 )
2018
17
Correction: Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. ( 29543881 )
2018
18
Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. ( 29332262 )
2018
19
Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. ( 28752843 )
2017
20
Fluorine-18-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computed Tomography Masquerading as a Case of Sporadic Malignant Peripheral Nerve Sheath Tumor of Lower Extremity Presenting as Massive Lower Limb Edema. ( 29033684 )
2017
21
Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor. ( 27706810 )
2017
22
Malignant peripheral nerve sheath tumor with and without neurofibromatosis type 1. ( 28658406 )
2017
23
Radiation-Induced Glandular Malignant Peripheral Nerve Sheath Tumor. ( 28530162 )
2017
24
The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells. ( 28502478 )
2017
25
Rexin-G(Ar), a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report. ( 28588778 )
2017
26
Malignant Peripheral Nerve Sheath Tumor of the Femur: A Rare Diagnosis Supported by Complete Immunohistochemical Loss of H3K27me3. ( 28508686 )
2017
27
Malignant Peripheral Nerve Sheath Tumor of the Inguinum and Angiosarcoma of the Scalp in a Child with Neurofibromatosis Type 1. ( 29138703 )
2017
28
Metastatic Epithelioid Malignant Peripheral Nerve Sheath Tumor in a Known Case of Neurofibromatosis-1, Cytomorphological Appearance, and Critical Analysis of Immunohistochemistry. ( 29200699 )
2017
29
Metastatic angiosarcoma arising in malignant peripheral nerve sheath tumor in a young patient with neurofibromatosis type 1. ( 28548697 )
2017
30
Role of Histone H3K27 Trimethylation Loss as a Marker for Malignant Peripheral Nerve Sheath Tumor in Fine-Needle Aspiration and Small Biopsy Specimens. ( 28898989 )
2017
31
CHD4 as a Potential Biomarker in Differentiating Between Cellular Schwannoma and Malignant Peripheral Nerve Sheath Tumor. ( 28549031 )
2017
32
Primary Intraosseous Malignant Peripheral Nerve Sheath Tumor of Metacarpal Bones of the Hand in a Patient Without Neurofibromatosis 1: Report of a Rare Case. ( 28900340 )
2017
33
Spindle cell type malignant peripheral nerve sheath tumor arising in benign schwannoma with multiple intraosseous spinal metastasis: A case report. ( 28505957 )
2017
34
Malignant peripheral nerve sheath tumor in children: A single-institute retrospective analysis. ( 29286874 )
2017
35
Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. ( 28558056 )
2017
36
Clinicopathological features and prognosis of malignant peripheral nerve sheath tumor: a retrospective study of 159 cases from 1999 to 2016. ( 29285213 )
2017
37
Acute hydrocephalus due to a primary malignant peripheral nerve sheath tumor of the cervicothoracic junction: A case report and review of the literature. ( 28502561 )
2017
38
Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors. ( 28124441 )
2017
39
Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors. ( 27477693 )
2017
40
NF1(+/-) Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response. ( 28646022 )
2017
41
Unusual primary breast cancer - malignant peripheral nerve sheath tumor: a case report and review of the literature. ( 28622765 )
2017
42
Malignant peripheral nerve sheath tumor of the vagus nerve: an uncommon cause of progressive dyspnea. ( 29307938 )
2017
43
Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. ( 28534510 )
2017
44
Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. ( 27875628 )
2017
45
Malignant Triton Tumor (Malignant Peripheral Nerve Sheath Tumor With Rhabdomyoblastic Differentiation) Occurring in a Vascularized Free Flap Reconstruction Graft. ( 28387148 )
2017
46
Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. ( 28813519 )
2017
47
Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. ( 28551330 )
2017
48
Doxycycline potentiates antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy in malignant peripheral nerve sheath tumor cells. ( 28558025 )
2017
49
Successful treatment with doxorubicin and ifosfamide for mediastinal malignant peripheral nerve sheath tumor with loss of H3K27me3 expression. ( 28876532 )
2017
50
Superficial malignant peripheral nerve sheath tumor with overlying intradermal melanocytic nevus mimicking spindle cell melanoma. ( 27687011 )
2016

Variations for Malignant Peripheral Nerve Sheath Tumor

Copy number variations for Malignant Peripheral Nerve Sheath Tumor from CNVD:

7 (show all 45)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17387 1 142600000 147000000 Gain Malignant peripheral nerve sheath tumor
2 22132 1 165500000 170900000 Gain Malignant peripheral nerve sheath tumor
3 23047 1 170900000 176000000 Gain Malignant peripheral nerve sheath tumor
4 49109 11 102900000 112500000 Loss Malignant peripheral nerve sheath tumor
5 49995 11 112500000 121200000 Loss Malignant peripheral nerve sheath tumor
6 53584 11 31000000 36400000 Loss Malignant peripheral nerve sheath tumor
7 61507 12 1 3100000 Gain FOXM1 Malignant peripheral nerve sheath tumor
8 65742 12 21200000 26300000 Amplification SOX5 Malignant peripheral nerve sheath tumor
9 66816 12 3300000 10100000 Gain Malignant peripheral nerve sheath tumor
10 67235 12 38200000 49100000 Gain Malignant peripheral nerve sheath tumor
11 69080 12 5300000 10000000 Gain NOL1 Malignant peripheral nerve sheath tumor
12 69882 12 56428269 56432431 Gain CDK4 Malignant peripheral nerve sheath tumor
13 69960 12 56600000 71500000 Gain Malignant peripheral nerve sheath tumor
14 71535 12 71500000 86700000 Gain Malignant peripheral nerve sheath tumor
15 73254 12 92600000 109000000 Gain Malignant peripheral nerve sheath tumor
16 73259 12 92600000 96200000 Gain Malignant peripheral nerve sheath tumor
17 75380 13 19500000 25500000 Gain Malignant peripheral nerve sheath tumor
18 76637 13 34000000 55300000 Gain Malignant peripheral nerve sheath tumor
19 79536 13 73300000 77200000 Gain Malignant peripheral nerve sheath tumor
20 85488 14 47200000 67900000 Loss Malignant peripheral nerve sheath tumor
21 87451 14 73800000 107349540 Gain Malignant peripheral nerve sheath tumor
22 97234 16 1 10500000 Gain Malignant peripheral nerve sheath tumor
23 102841 16 57400000 90354753 Gain Malignant peripheral nerve sheath tumor
24 105377 16 7900000 14800000 Gain Malignant peripheral nerve sheath tumor
25 115613 17 58300000 81195210 Gain Malignant peripheral nerve sheath tumor
26 124065 19 1 13900000 Gain Malignant peripheral nerve sheath tumor
27 147242 2 61300000 68600000 Gain Malignant peripheral nerve sheath tumor
28 150135 2 96800000 114400000 Gain Malignant peripheral nerve sheath tumor
29 163892 22 32200000 44200000 Gain Malignant peripheral nerve sheath tumor
30 172609 3 184500000 198022430 Gain Malignant peripheral nerve sheath tumor
31 174546 3 2800000 16400000 Gain Malignant peripheral nerve sheath tumor
32 175421 3 39400000 54400000 Gain Malignant peripheral nerve sheath tumor
33 196162 5 159900000 180915260 Gain Malignant peripheral nerve sheath tumor
34 198008 5 18400000 23300000 Gain Malignant peripheral nerve sheath tumor
35 209673 6 27000000 57000000 Gain Malignant peripheral nerve sheath tumor
36 213890 6 52900000 70000000 Gain Malignant peripheral nerve sheath tumor
37 220382 7 13800000 43300000 Gain Malignant peripheral nerve sheath tumor
38 227906 7 72200000 86400000 Gain Malignant peripheral nerve sheath tumor
39 240607 8 52600000 146364022 Gain Malignant peripheral nerve sheath tumor
40 241476 8 6200000 36500000 Gain Malignant peripheral nerve sheath tumor
41 244863 9 1 14200000 Gain Malignant peripheral nerve sheath tumor
42 247559 9 130300000 135900000 Gain Malignant peripheral nerve sheath tumor
43 249423 9 14200000 28000000 Loss Malignant peripheral nerve sheath tumor
44 255080 9 72339785 73251640 Dramatically overexp ressed,genomicallyamplified TRPM3 Malignant peripheral nerve sheath tumor
45 255774 9 84100000 102600000 Gain Malignant peripheral nerve sheath tumor

Expression for Malignant Peripheral Nerve Sheath Tumor

Search GEO for disease gene expression data for Malignant Peripheral Nerve Sheath Tumor.

Pathways for Malignant Peripheral Nerve Sheath Tumor

Pathways related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 CDK4 CDKN2A EGFR KIT MDM2 MUC1
2
Show member pathways
13.34 EGFR KIT MUC1 NF1 NRG1 PDGFRA
3
Show member pathways
13.1 EGFR KIT MDM2 NRG1 PDGFRA TP53
4
Show member pathways
13.04 EGFR KIT MDM2 NRG1 PDGFRA TP53
5
Show member pathways
12.96 CDK4 EGFR KIT MDM2 PDGFRA TP53
6
Show member pathways
12.78 CDK4 CDKN2A EGFR KIT MDM2 PDGFRA
7 12.74 EGFR KIT NF1 PDGFRA TP53
8
Show member pathways
12.74 CDK4 CDKN2A EGFR KIT SMARCB1 TP53
9 12.72 CDK4 CDKN2A EGFR KIT MDM2 PDGFRA
10
Show member pathways
12.71 EGFR KIT MDM2 NRG1 PDGFRA TP53
11
Show member pathways
12.55 CDK4 CDKN2A MDM2 TOP2A TP53
12
Show member pathways
12.52 EGFR MDM2 MUC1 NRG1 TP53
13
Show member pathways
12.42 EGFR MDM2 PDGFRA TP53
14 12.4 CDK4 CDKN2A PDGFRA TP53
15 12.39 CDKN2A EGFR MDM2 PDGFRA TP53 VIM
16
Show member pathways
12.36 CDK4 CDKN2A MDM2 TP53
17 12.35 CDK4 CDKN2A MDM2 TP53
18 12.32 CDK4 CDKN2A MDM2 TOP2A TP53 VIM
19 12.28 CDK4 CDKN2A MDM2 TP53
20
Show member pathways
12.23 CDK4 CDKN2A EGFR MDM2 NF1 NRG1
21 12.16 CDK4 CDKN2A MDM2 TP53
22 12.11 EGFR KIT NRG1 PDGFRA
23 12.11 CDK4 EGFR MDM2 PDGFRA TP53
24 12.06 CDK4 EGFR MDM2 NF1 TP53
25
Show member pathways
12.05 CDK4 EGFR PDGFRA
26
Show member pathways
12.04 CDK4 EGFR NF1 NRG1
27 11.99 CDK4 EGFR TP53 VIM
28
Show member pathways
11.94 EGFR MDM2 NRG1 S100B
29 11.81 CDK4 MDM2 TOP2A TP53
30 11.75 PDGFRA S100B SOX10 VIM
31
Show member pathways
11.72 CDKN2A MDM2 TP53
32 11.69 CDKN2A MDM2 TOP2A TP53
33 11.62 EGFR KIT PDGFRA TP53
34 11.59 CDK4 NF1 PDGFRA
35 11.57 CDKN2A MDM2 TP53
36
Show member pathways
11.57 MDM2 TOP2A TP53
37 11.49 CDK4 MDM2 TP53
38 11.47 CDK4 MDM2 TP53
39 11.43 ACTC1 KIT NRG1 PDGFRA
40 11.42 CDK4 CDKN2A EGFR MDM2 TP53
41 11.33 CDKN2A EGFR PDGFRA TP53
42 11.31 EGFR TOP2A TP53
43 11.27 CDK4 CDKN2A EGFR MDM2 NF1 NF2
44 11.1 CDKN2A MDM2 TP53
45
Show member pathways
11.09 CDKN2A MDM2 TP53
46 11.06 CDK4 CDKN2A MDM2 TP53

GO Terms for Malignant Peripheral Nerve Sheath Tumor

Cellular components related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.76 CDK4 CDKN2A MDM2 NF1 NF2 SMARCB1
2 cytoplasm GO:0005737 9.6 ACTC1 CDK4 CDKN2A EGFR HTRA1 KIT
3 cell body GO:0044297 9.5 ACTC1 NF2 NRG1
4 protein-containing complex GO:0032991 9.5 EGFR MDM2 PDGFRA S100A1 SMARCB1 TOP2A
5 nucleus GO:0005634 10.13 CDK4 CDKN2A EGFR MDM2 MUC1 NF1

Biological processes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.99 MDM2 PDGFRA SMARCB1 TP53 VIM
2 negative regulation of cell proliferation GO:0008285 9.97 CDKN2A NF1 NF2 SMARCB1 TP53
3 negative regulation of apoptotic process GO:0043066 9.97 ACTC1 EGFR KIT MDM2 PDGFRA TP53
4 MAPK cascade GO:0000165 9.85 EGFR KIT NF1 NRG1 PDGFRA
5 peptidyl-tyrosine phosphorylation GO:0018108 9.84 EGFR KIT NRG1 PDGFRA
6 regulation of cell proliferation GO:0042127 9.83 CDK4 EGFR KIT NF1 NF2
7 protein sumoylation GO:0016925 9.81 CDKN2A MDM2 TOP2A
8 positive regulation of protein kinase B signaling GO:0051897 9.81 EGFR KIT NRG1 PDGFRA
9 Ras protein signal transduction GO:0007265 9.8 CDKN2A NF1 TP53
10 positive regulation of kinase activity GO:0033674 9.79 EGFR KIT PDGFRA
11 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 KIT NRG1 PDGFRA
12 cellular response to drug GO:0035690 9.76 EGFR SOX10 TP53
13 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.73 MDM2 MUC1 TP53
14 positive regulation of apoptotic process GO:0043065 9.73 CDK4 CDKN2A NF1 S100B TOP2A TP53
15 positive regulation of fibroblast proliferation GO:0048146 9.72 CDK4 EGFR PDGFRA
16 phosphatidylinositol phosphorylation GO:0046854 9.71 EGFR KIT NRG1 PDGFRA
17 wound healing GO:0042060 9.67 EGFR NF1 NRG1 PDGFRA
18 replicative senescence GO:0090399 9.64 CDKN2A TP53
19 tongue development GO:0043586 9.64 EGFR KIT
20 somatic stem cell division GO:0048103 9.62 CDKN2A KIT
21 amyloid fibril formation GO:1990000 9.61 CDKN2A MDM2
22 positive regulation of phospholipase C activity GO:0010863 9.61 KIT PDGFRA
23 negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.57 CDK4 CDKN2A
24 positive regulation of histone H4 acetylation GO:0090240 9.52 MUC1 SMARCB1
25 negative regulation of cell-matrix adhesion GO:0001953 9.5 CDKN2A NF1 NF2
26 positive regulation of cell proliferation GO:0008284 9.5 CDK4 EGFR KIT MDM2 NRG1 PDGFRA
27 cellular response to actinomycin D GO:0072717 9.48 MDM2 TP53
28 positive regulation of myelination GO:0031643 9.33 NRG1 S100B SOX10
29 positive regulation of gene expression GO:0010628 9.23 ACTC1 CDKN2A KIT MDM2 NRG1 SOX10

Molecular functions related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.76 EGFR HTRA1 MDM2 S100A1 S100B SOX10
2 protein tyrosine kinase activity GO:0004713 9.73 EGFR KIT NRG1 PDGFRA
3 MAP kinase kinase kinase activity GO:0004709 9.69 EGFR KIT PDGFRA
4 mitogen-activated protein kinase kinase binding GO:0031434 9.65 EGFR KIT PDGFRA
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.63 EGFR KIT PDGFRA
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.56 EGFR KIT NRG1 PDGFRA
7 growth factor binding GO:0019838 9.54 HTRA1 KIT PDGFRA
8 disordered domain specific binding GO:0097718 9.5 CDKN2A MDM2 TP53
9 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.49 EGFR KIT
10 p53 binding GO:0002039 9.26 MDM2 MUC1 SMARCB1 TP53
11 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.92 EGFR KIT NRG1 PDGFRA
12 protein binding GO:0005515 10.36 CDK4 CDKN2A EGFR HTRA1 KIT MDM2

Sources for Malignant Peripheral Nerve Sheath Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....